Abstract
Plasma content of copeptin increases with the advancement of chronic kidney disease (CKD). The purpose of this study was to evaluate copeptin content as a potential marker of CKD, as a single pathology or with coexisting heart failure. Seventy-six patients were divided into the following groups: Group 1 (control), without CKD and heart failure; Group 2, CKD stage 3a; Group 3, CKD stage 3b; Group 4, CKD stage 4; Group 5, CKD stage 5; and Group 6, CKD stage 3b and heart failure. For all patients, plasma concentrations of copeptin, creatinine, urea, cystatin C, sodium, C-reactive protein (CRP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and blood pH were assessed. We found that plasma content of creatinine, urea, CRP, cystatin, NT-proBNP, and copeptin increased with CKD progression. Heart failure in CKD patients was not the cause of an appreciable increase of copeptin level. Copeptin/creatinine, copeptin/cystatin C ratios, and especially copeptin/eGFR ratio enhanced copeptin prognostic sensitivity concerning renal failure in CKD, compared with copeptin alone. The copeptin×NT-proBNP ratio decreased along CKD progression, reaching a nadir in the accompanying heart failure. In contradistinction, copeptin×NT-proBNP/creatinine ratio increased along CKD progression, reaching a peak in the accompanying heart failure. We conclude that copeptin is an important marker in CKD, but not so concerning heart failure in the disease. A decrease in copeptin×NT-proBNP and an increase in copeptin×NT-proBNP/creatinine ratio are useful markers of cardiac function decline in CKD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Afsar B (2017) Pathophysiology of copeptin in kidney disease and hypertension. Clin Hypertens 23:13
Bankir L, Bardoux P, Ahloulay M (2001) Vasopressin and diabetes mellitus. Nephron 87:8–18
Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL (2009) Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116:257–263
Boeck L, Eggimann P, Smyrnios N, Pargger H, Thakkar N, Siegemund M, Morgenthaler NG, Rakic J, Tamm M, Stolz D (2012) The Sequential Organ Failure Assessment score and copeptin for predicting survival in ventilator-associated pneumonia. J Crit Care 27:523.e1–523.e9
Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, Struck J, Bakker SJ, Peters DJ, de Jong PE, Gansevoort RT (2012) Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 27:4131–4137
De Marchis GM, Katan M, Weck A, Fluri F, Foerch C, Findling O, Schuetz P, Buhl D, El-Koussy M, Gensicke H, Seiler M, Morgenthaler N, Mattle HP, Mueller B, Christ-Crain M, Arnold M (2013) Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology 80:1278–1286
Engelbertz C, Brand E, Fobker M, Fischer D, Pavenstädt H, Reinecke H (2016) Elevated copeptin is a prognostic factor for mortality even in patients with renal dysfunction. Int J Cardiol 221:327–332
Fenske W, Wanner C, Allolio B, Drechsler C, Blouin K, Lilienthal J, Krane V, German Diabetes, Dialysis Study Investigators (2011) Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol 22:782–790
Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A (2005) Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem 38:1–8
Fogo AB (2006) Progression versus regression of chronic kidney disease. Nephrol Dial Transplant 21:281–284
Hooper L, Abdelhamid A, Ali A, Bunn DK, Jennings A, John WG, Kerry S, Lindner G, Pfortmueller CA, Sjöstrand F, Walsh NP, Fairweather-Tait SJ, Potter JF, Hunter PR, Shepstone L (2015) Diagnostic accuracy of calculated serum osmolarity to predict dehydration in older people: adding value to pathology laboratory reports. BMJ Open 5:e008846
Hu W, Ni YJ, Ma L, Hao HR, Chen L, Yu WN (2015) Serum copeptin as a new biomarker in the early diagnosis of decline in renal function of type 2 diabetes mellitus patients. Int J Clin Exp Med 8:9730–9736
Jochberger S, Dörler J, Luckner G, Mayr VD, Wenzel V, Ulmer H, Morgenthaler NG, Hasibeder WR, Dünser MW (2009) The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med 37:476–482
Katan M, Christ-Crain M (2010) The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 140:w13101
Lane BR, Poggio ED, Herts BR, Novick AC, Campbell SC (2009) Renal function assessment in the era of chronic kidney disease: renewed emphasis on renal function centered patient care. J Urol 182:435–443
Levey AS, Greene T, Kusek JW, Beck GL, MDRD Study Group (2000) A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 11:155A
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A (2012) ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847
Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M (2007) Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 28:219–226
Niizuma S, Iwanaga Y, Yahata T, Tamaki Y, Goto Y, Nakahama H, Miyazaki S (2009) Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. Clin Chem 55:1347–1353
Plischke M, Kohl M, Bankir L, Shayganfar S, Handisurya A, Heinze G, Haas M (2014) Urine osmolarity and risk of dialysis initiation in a chronic kidney disease cohort–a possible titration target? PLoS One 9:e93226
Ponte B, Pruijm M, Ackermann D, Vuistiner P, Guessous I, Ehret G, Alwan H, Youhanna S, Paccaud F, Mohaupt M, Péchère-Bertschi A, Vogt B, Burnier M, Martin PY, Devuyst O, Bochud M (2015) Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study. J Am Soc Nephrol 6:1415–1425
Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, Lantieri O, Balkau B, Bouby N, Bankir L, Bichet DG (2014) Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 99:4656–4663
Roussel R, Matallah N, Bouby N, El Boustany R, Potier L, Fumeron F, Mohammedi K, Balkau B, Marre M, Bankir L, Velho G (2015) Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. Study. Am J Nephrol 42:107–114
Tasevska I, Enhörning S, Christensson A, Persson M, Nilsson PM, Melander O (2016) Increased levels of copeptin, a surrogate marker of arginine vasopressin, are associated with an increased risk of chronic kidney disease in a general population. Am J Nephrol 44:22–28
Tesch GH (2010) Review: serum and urine biomarkers of kidney disease: a pathophysiological perspective. Nephrology (Carlton) 15:609–616
Vuilleumier N, Simona A, Méan M, Limacher A, Lescuyer P, E G, Bounameaux H, Aujesky D, Righini M (2016) Comparison of cardiac and non-cardiac biomarkers for risk stratification in elderly patients with non-massive pulmonary embolism. PLoS 11:e0155973
Yasuda K, Kimura T, Sasaki K, Obi Y, Iio K, Yamato M, Rakugi H, Isaka Y, Hayashi T (2012) Plasma B-type natriuretic peptide level predicts kidney prognosis in patients with predialysis chronic kidney disease. Nephrol Dial Transplant 27:3885–3891
Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, Meijer E, Gansevoort RT (2012) Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol 7:906–913
Zittema D, van den Berg E, Meijer E, Boertien WE, Muller Kobold AC, Franssen CF, de Jong PE, Bakker SJ, Navis G, Gansevoort RT (2014) Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 9:1553–1562
Acknowledgments
Funded by a grant no. 307 from the Military Institute of Medicine. This research was carried out with the use of CePT infrastructure financed by the European Union Regional Development Fund within the Operational Program “Innovative Economy” for 2007–2013.
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Niemczyk, S. et al. (2018). Copeptin Blood Content as a Diagnostic Marker of Chronic Kidney Disease. In: Pokorski, M. (eds) Rehabilitation Science in Context . Advances in Experimental Medicine and Biology(), vol 1096. Springer, Cham. https://doi.org/10.1007/5584_2018_189
Download citation
DOI: https://doi.org/10.1007/5584_2018_189
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95707-4
Online ISBN: 978-3-319-95708-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)